Skip to main content

Tyra Biosciences, Inc. (TYRA)

NASDAQ: TYRA · Delayed Price · USD
19.82 1.27 (6.85%)
Sep 21, 2021 4:00 PM EDT - Market closed
Market Cap810.94M
Revenue (ttm)n/a
Net Income (ttm)-15.75M
Shares Out40.92M
EPS (ttm)-0.38
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume-
Open-
Previous Close18.55
Day's Range18.50 - 23.89
52-Week Range0.00 - 23.89
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About TYRA

Tyra Biosciences is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Despite the therapeutic benefit that targeted oncology treatments have created for some patients, the response rate and duration of efficacy is often limited by acquired drug resistance and other shortcomings of existing therapies. We are using our proprietary SNÅP platform in order to generate next-generation product candidates that are specifically designed to address acqui...

IndustryBiotechnology
IPO DateSep 15, 2021
CEOTodd Harris, Ph.D.
Employees16
Stock ExchangeNASDAQ
Ticker SymbolTYRA
Full Company Profile

Financial Performance

Financial Statements

News

Tyra Announces Pricing of Upsized Initial Public Offering

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance...

6 days ago - PRNewswire

Tyra Biosciences IPO Registration Document (S-1)

Tyra Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC